SI
SION.US Sionna Therapeutics, Inc. Common Stock
- Market cap
- USD 139M
- P/E
- -
- P/B
- 0.59x
- ROE
- -49.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is SION.US undervalued?
Graham numberThe Graham number of Sionna Therapeutics, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sionna Therapeutics, Inc. Common Stock fundamental analysis
No fundamental analysis for Sionna Therapeutics, Inc. Common Stock yet.
Sionna Therapeutics, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sionna Therapeutics, Inc. Common Stock
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 tria…
Full company profileSionna Therapeutics, Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Sionna Therapeutics, Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | - | - | -668K | -647K | - |
| Operating Income | -41.4M | -50.3M | -70.6M | -89.0M | -121M |
| EBITDA | -40.1M | -46.7M | -61.0M | -74.6M | -113M |
| Net Income | -40.2M | -47.3M | -61.7M | -75.3M | -119M |
| EPS | -0.91 | -1.07 | -1.40 | -1.88 | -2.63 |
| Balance Sheet | |||||
| Total Assets | 87.4M | 51.9M | 186M | 326M | 263M |
| Total Liabilities | 157M | 167M | 349M | 19.1M | 22.7M |
| Shareholders' Equity | -69.9M | -115M | -164M | 307M | 241M |
| Cash & Short-term Investments | 82.6M | 38.5M | 148M | 236M | 225M |
| Total Debt | - | 10.5M | 9.75M | 8.68M | 7.75M |
| Cash Flow | |||||
| Operating Cash Flow | -36.1M | -43.7M | -52.8M | -66.3M | -113M |
| Capital Expenditure | 1.87M | 1.12M | 27.0K | 377K | 0.00 |
| Free Cash Flow | -37.9M | -44.8M | -52.8M | -66.7M | -113M |
| Ratios | |||||
| ROE | - | - | - | -24.5% | -49.4% |
| ROA | -46.1% | -91.0% | -33.2% | -23.1% | -45.1% |
| Debt to Equity | - | - | - | 0.03x | 0.03x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Sionna Therapeutics, Inc. Common Stock dividends
Sionna Therapeutics, Inc. Common Stock has not paid dividends in the last 4 fiscal years.
Who owns Sionna Therapeutics, Inc. Common Stock
- Insiders 7.87%
- Institutions 92.13%
- Public & others 0.00%
- Shares outstanding 45.2M
- Free float 20.5M
Top funds holding SION.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| abrdn Healthcare Investors | 1.53M | 3.38% | 0.00% | Oct 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 935K | 2.07% | 0.00% | Sep 2026 |
| PGIM Jennison Health Sciences Z | 934K | 2.06% | 0.00% | Sep 2026 |
| abrdn Life Sciences Investors | 753K | 1.66% | +63.91% | Oct 2026 |
| Eventide Healthcare & Life Sciences I | 475K | 1.05% | -26.31% | Jun 2026 |
| iShares Russell 2000 ETF | 473K | 1.05% | 0.00% | Oct 2026 |
| Candriam Eqs L Biotech C USD Cap | 237K | 0.52% | 0.00% | Apr 2026 |
| iShares Biotechnology ETF | 207K | 0.46% | -0.19% | Oct 2026 |
| iShares Russell 2000 Growth ETF | 175K | 0.39% | -0.38% | Oct 2026 |
| Fidelity Extended Market Index | 120K | 0.27% | 0.00% | Sep 2026 |
| Vanguard Russell 2000 ETF | 116K | 0.26% | +9.69% | Sep 2026 |
| Vanguard Explorer Inv | 111K | 0.25% | 0.00% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 102K | 0.22% | +0.22% | Oct 2026 |
| UTM IM GBP AXA Framlington Biotech | 72.5K | 0.16% | 0.00% | Sep 2026 |
| Bridge Builder Small Cap Fund | 56.8K | 0.13% | 0.00% | Oct 2026 |
| ALPS Medical Breakthroughs ETF | 54.9K | 0.12% | 0.00% | Oct 2026 |
| Vanguard Health Care ETF | 48.9K | 0.11% | +18.94% | Sep 2026 |
| Schwab Small Cap Index | 44.7K | 0.10% | 0.00% | Sep 2026 |
| iShares Nasdaq US Biotech ETF USD Acc | 38.4K | 0.08% | +0.21% | Oct 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 34.5K | 0.08% | 0.00% | Sep 2026 |
Top institutions holding SION.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| RA Capital Management, LLC | 9.91M | 21.90% | 0.00% | Jun 2026 |
| TPG GP A, LLC | 6.49M | 14.36% | 0.00% | Jun 2026 |
| Viking Global Investors LP | 3.20M | 7.06% | 0.00% | Jun 2026 |
| Atlas Venture Life Science Advisors, LLC | 3.00M | 6.62% | 0.00% | Jun 2026 |
| Orbimed Advisors LLC | 2.56M | 5.65% | -27.61% | Jun 2026 |
| Enavate Sciences GP, LLC | 2.48M | 5.48% | 0.00% | Jun 2026 |
| Adage Capital Partners Gp LLC | 1.60M | 3.54% | +966.67% | Jun 2026 |
| JPMorgan Chase & Co | 1.49M | 3.30% | +1.74% | Jun 2026 |
| BlackRock Inc | 1.47M | 3.26% | +13.81% | Jun 2026 |
| Aberdeen Group PLC | 1.34M | 2.97% | +372.71% | Sep 2026 |
| Jennison Associates LLC | 1.17M | 2.59% | -19.23% | Jun 2026 |
| Citadel Advisors Llc | 1.15M | 2.54% | -1.65% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.13M | 2.50% | +9.96% | Jun 2026 |
| State Street Corp | 1.02M | 2.26% | +35.08% | Jun 2026 |
| Perceptive Advisors LLC | 905K | 2.00% | +37.45% | Jun 2026 |
| Deerfield Management Co | 681K | 1.51% | -29.85% | Jun 2026 |
| Siren, L.L.C. | 611K | 1.35% | +103.51% | Jun 2026 |
| Acadian Asset Management LLC | 554K | 1.22% | 0.00% | Sep 2026 |
| T. Rowe Price Associates, Inc. | 478K | 1.06% | -36.80% | Jun 2026 |
| Eventide Asset Management, LLC | 475K | 1.05% | -26.42% | Jun 2026 |
Sionna Therapeutics, Inc. Common Stock company profile
- Company name
- Sionna Therapeutics, Inc. Common Stock
- Ticker
- SION.US
- Exchange
- USA Stocks
- Listed since
- Feb 7, 2025
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 59
- Fiscal year end
- December
- Address
- 21 Hickory Drive, Waltham, MA, United States, 02451
- Phone
- 617 819 2020
- Website
- sionnatx.com
About Sionna Therapeutics, Inc. Common Stock
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Sionna Therapeutics, Inc. Common Stock management
10- Mr. Michael Cloonan M.B.A.President, CEO & Director · born 1971
- Ms. Elena H. Ridloff C.F.A.CFO & Chief Business Officer · born 1980
- Dr. Greg Hurlbut Ph.D.Co-Founder & Senior VP of Discovery Research
- Dr. Mark Munson Ph.D.Co-founder
- Mr. Andy ChuVice President of Information & Technology
- Juliet LabadorfSenior Director of Investor Relations & Corporate Development
- Ms. Jennifer Fitzpatrick J.D.Chief Legal Officer & Head of Program Management · born 1977
- Ms. Roxanne McGrathVice President of Head of Human Resources
- Dr. Charlotte McKee M.D.Chief Medical Officer & Head of Research and Development · born 1965
- Ms. Mara Furlow M.S.Senior Vice President of Global Regulatory Affairs & Quality